B+
Bull case
25%
Probability
Target price
$0.85
-96.8% vs current
CUE
Cue BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.38
-98.6% vs current
B-
Bear case
30%
Probability
Target price
$0.14
-99.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Net sentiment remains cautious-positive but low conviction. The deterministic prior is mildly positive, yet the strongest live evidence is still balance-sheet and listing defense rather than clean operating momentum: April 13 confirmed reverse-split authorization, while the March 16 10-K emphasized Nasdaq pressure, a need for additional capital, and substantial doubt about continuing as a going concern. This still reads as a monitoring-style distressed biotech setup, not a clean fundamental re-rating story [#8-K-2026-04-13] [#10-K-2026-03-16].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-11eventBoard decision on implementing the approved reverse split before Nasdaq deadlineHigh impact
Cue's stockholders approved a reverse split range of 1-for-30 to 1-for-50 on April 13, 2026, and the board retains sole discretion on exact ratio and timing. That decision now sits directly against the May 11, 2026 end of Cue's second Nasdaq bid-price compliance period, making listing preservation a near-term liquidity and financing access catalyst rather than a fundamental operating win [#8-K-2026-04-13] [#10-K-2026-03-16].
2026-11-06eventImmunoScape's additional payment is the clearest non-dilutive cash checkpointHigh impact
Cue disclosed that ImmunoScape exercised its option on November 6, 2025, that Cue received cash plus equity consideration in Q4 2025, and that Cue is entitled to an additional $5.0 million before the first anniversary of the effective collaboration date. Receipt would help validate collaboration monetization, but it is too small by itself to eliminate financing risk [#10-K-2026-03-16].
2026-12-31catalystFinancing or strategic funding remains the core medium-term stock driverHigh impact
The 10-K says Cue had $27.1 million of cash at December 31, 2025 and believes that cash can fund operations into the first quarter of 2027, but it also states the company will need to raise substantial additional capital and concluded that substantial doubt exists about its ability to continue as a going concern within one year of filing. That keeps future funding terms, dilution, or partnership structure as the main thesis variable [#10-K-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology